date,title,source
Oct-17-18,ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis,GlobeNewswire
Oct-22-18,New Data Presented on ASLANs varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients,GlobeNewswire
Oct-30-18,ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director,GlobeNewswire
Nov-01-18,ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting,GlobeNewswire
